QFREF yields 158.73% · JNJ yields 2.14%● Live data
📍 QFREF pulled ahead of the other in Year 1
Combined, QFREF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of QFREF + JNJ for your $10,000?
Q-Free ASA supplies intelligent transportation system products and solutions worldwide. It offers tolling products, such as dedicated short-range communication on-board units, roadside transceivers/antennas, handheld transceivers/digital tachographs, and automated license plate recognition (ALPR) cameras/imaging systems. The company also provides Intrada ALPR, an automatic license plate recognition and vehicle analytics solution; Intrada Insight, an image processing and review solution; and Intrada Synergy Server, an image processing solution for video-based passages, such as tolling and parking/access control. In addition, it offers traffic management products, including Urban hardware, such as ATC controllers and cabinets; urban software comprising central and local traffic control software systems, as well as ramp meter, analytics, adaptive, and connected vehicle software enhancements; interurban software, such as Statewide ATMS, a statewide freeway traffic management software system, as well as software enhancements for work zone and event management; and infomobility hardware products, including high- and low-speed weigh-in-motion systems, as well as traffic counting and classification products for vehicles, bicycles, and pedestrians. The company also provides maintenance services. Q-Free ASA was founded in 1984 and is headquartered in Trondheim, Norway.
Full QFREF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.